Phaseline

Targets › CHM

CHM (Rab proteins geranylgeranyltransferase component A 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout May 2027.

Substrate-binding subunit of the Rab geranylgeranyltransferase (GGTase) complex. Binds unprenylated Rab proteins and presents the substrate peptide to the catalytic component B composed of RABGGTA and RABGGTB, and remains bound to it after the geranylgeranyl transfer reaction. (UniProt, P24386)

Open in Phaseline: the race on CHM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
4D Molecular Therapeutics4D-110
AAV gene therapy delivering codon-optimized human CHM gene via AAV5 capsid variant (4D-R10
CHMPhase 1ChoroideremiaMay 2027

Conditions

Choroideremia (1)

Modalities

protein or peptide (1)

Companies

4D Molecular Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.